Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

566 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality.
Jurado M, Deeg HJ, Storer B, Anasetti C, Anderson JE, Bryant E, Chauncey T, Doney K, Flowers ME, Hansen J, Martin PJ, Nash RA, Petersdorf E, Radich J, Sale G, Sandmaier BM, Storb R, Wade J, Witherspoon R, Appelbaum FR. Jurado M, et al. Biol Blood Marrow Transplant. 2002;8(3):161-9. doi: 10.1053/bbmt.2002.v8.pm11939606. Biol Blood Marrow Transplant. 2002. PMID: 11939606 Free article. Clinical Trial.
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.
Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, Kiem HP, Martin PJ, Petersdorf E, Radich JP, Sanders JE, Shulman HM, Warren EH, Witherspoon RP, Bryant EM, Chauncey TR, Getzendaner L, Storb R, Appelbaum FR. Deeg HJ, et al. Among authors: hansen ja. Blood. 2002 Aug 15;100(4):1201-7. doi: 10.1182/blood-2002-02-0527. Blood. 2002. PMID: 12149198 Free article. Clinical Trial.
Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation.
Martin PJ, Pei J, Gooley T, Anasetti C, Appelbaum FR, Deeg J, Hansen JA, Nash RA, Petersdorf EW, Storb R, Ghetie V, Schindler J, Vitetta ES. Martin PJ, et al. Among authors: hansen ja. Biol Blood Marrow Transplant. 2004 Aug;10(8):552-60. doi: 10.1016/j.bbmt.2004.04.002. Biol Blood Marrow Transplant. 2004. PMID: 15282533 Free article. Clinical Trial.
Duration of immunosuppressive treatment for chronic graft-versus-host disease.
Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA, Appelbaum FR, Carpenter PA, Sanders JE, Kiem HP, Nash RA, Petersdorf EW, Moravec C, Morton AJ, Anasetti C, Flowers ME, Martin PJ. Stewart BL, et al. Among authors: hansen ja. Blood. 2004 Dec 1;104(12):3501-6. doi: 10.1182/blood-2004-01-0200. Epub 2004 Aug 3. Blood. 2004. PMID: 15292060 Free article.
Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor.
Lin MT, Storer B, Martin PJ, Tseng LH, Grogan B, Chen PJ, Zhao LP, Hansen JA. Lin MT, et al. Among authors: hansen ja. Blood. 2005 Dec 1;106(12):3995-4001. doi: 10.1182/blood-2004-11-4338. Epub 2005 Aug 18. Blood. 2005. PMID: 16109775 Free PMC article.
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.
Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D, Heimfeld S, Flowers ME, Anasetti C, Doney KC, Hansen JA, Kiem HP, Nash RA, O'Donnell PV, Radich JP, Sandmaier BM, Scott BL, Sorror ML, Warren EH, Witherspoon RP, Woolfrey A, Appelbaum FR, Storb R. Deeg HJ, et al. Among authors: hansen ja. Biol Blood Marrow Transplant. 2006 May;12(5):573-84. doi: 10.1016/j.bbmt.2005.12.036. Biol Blood Marrow Transplant. 2006. PMID: 16635793 Free article. Clinical Trial.
566 results